EYES - Second Sight Medical Products Looks Overvalued
- The company develops retinal prosthesis systems, which visually remind me of the eyePhone from Futurama.
- Second Sight Medical Products is merging with a French sector player and its valuation stands at around $515 million.
- However, Second Sight ceased production activities in 2019 after sales of its Argus II product were weak for years.
- It seems the company is popular on social media platforms and there could be a significant retail investor interest at the moment.
- I think the business isn't worth much in its current state and that Second Sight is a sell.
For further details see:
Second Sight Medical Products Looks Overvalued